



AKT3 gene

AKT serine/threonine kinase 3

Normal Function

The *AKT3* gene provides instructions for making a protein that is most active in the nervous system. The AKT3 protein is a key regulator of a chemical signaling pathway called the PI3K-AKT-mTOR pathway. This signaling influences many critical cell functions, including the creation (synthesis) of new proteins, cell growth and division (proliferation), and the survival of cells. The PI3K-AKT-mTOR pathway is essential for the normal development of many parts of the body, including the brain. Studies suggest that the AKT3 protein plays a critical role in determining brain size.

Health Conditions Related to Genetic Changes

megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome

Several mutations in the *AKT3* gene have been found to cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndrome. This rare condition affects the development of the brain, causing an unusually large brain and head size (megalencephaly) and other abnormalities of the brain's structure.

Each of the known mutations changes a single protein building block (amino acid) in the AKT3 protein. These changes are described as "gain-of-function" because they increase the activity of the protein. This enhanced activity increases chemical signaling through the PI3K-AKT-mTOR pathway, which causes excessive cell growth and division. The increased number of cells leads to rapid and abnormal brain growth starting before birth.

other disorders

Changes involving the *AKT3* gene are also involved in other disorders of brain growth. Megalencephaly without the other features of MPPH syndrome (described above) has been associated with gain-of-function *AKT3* gene mutations or extra copies (duplication) of the region of chromosome 1 containing the *AKT3* gene. These genetic changes increase the amount or activity of the AKT3 protein, which enhances chemical signaling through the PI3K-AKT-mTOR pathway and causes excessive cell growth and division, particularly in the brain.

Other genetic changes involving the *AKT3* gene are associated with an unusually small brain and head size (microcephaly). These changes include a deletion of the *AKT3* gene or a loss of the region of chromosome 1 containing the *AKT3* gene. The resulting reduction in AKT3 protein activity likely decreases signaling through the


PI3K-AKT-mTOR pathway and restricts cell growth and division in the developing brain.

Changes involving the *AKT3* gene can also cause a brain malformation called isolated hemimegalencephaly. This brain abnormality is an enlargement of one of the two major halves (hemispheres) of the cerebrum, which is the large part of the brain that controls most voluntary activity, language, sensory perception, learning, and memory. Like the genetic changes that cause MPPH syndrome and megalencephaly (described above), the *AKT3* gene changes that result in isolated hemimegalencephaly are gain-of-function, ultimately leading to increased cell growth and division in the developing brain. However, unlike the mutations that cause those other abnormalities of brain growth, the genetic changes related to isolated hemimegalencephaly are somatic, meaning they occur at some point during embryonic development. As brain cells continue to grow and divide, some of these cells will have the genetic change, and others will not (a situation known as mosaicism). The mosaic nature of these genetic changes helps explain why they cause overgrowth in only one of the two cerebral hemispheres.

Chromosomal Location

Cytogenetic Location: 1q43-q44, which is the long (q) arm of chromosome 1 between positions 43 and 44

Molecular Location: base pairs 243,488,233 to 243,851,079 on chromosome 1 (Homo sapiens Annotation Release 108, GRCh38.p7) (NCBI)



Credit: Genome Decoration Page/NCBI

Other Names for This Gene

- PKB-GAMMA
- PKB gamma
- PKBG
- PRKBG
- RAC-gamma

- RAC-gamma serine/threonine protein kinase
- RAC-PK-gamma
- STK-2
- v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)

Additional Information & Resources

Educational Resources

- Madame Curie Bioscience Database: Signaling Kinases Pro- and Anti-Apoptotic Effectors in the Nervous System
<https://www.ncbi.nlm.nih.gov/books/NBK6319/#A992>
- Marie Curie Bioscience Database: PI-3K and AKT Signalling Pathway
<https://www.ncbi.nlm.nih.gov/books/NBK5964/#A40945>

GeneReviews

- MPPH Syndrome
<https://www.ncbi.nlm.nih.gov/books/NBK396098>

Scientific Articles on PubMed

- PubMed
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28AKT3%5BTIAB%5D%29+OR+%28AKT+serine/threonine+kinase+3%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D>

OMIM

- V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3
<http://omim.org/entry/611223>

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
<http://atlasgeneticsoncology.org/Genes/AKT3ID615ch1q44.html>
- ClinVar
<https://www.ncbi.nlm.nih.gov/clinvar?term=AKT3%5Bgene%5D>
- HGNC Gene Family: Pleckstrin homology domain containing
<http://www.genenames.org/cgi-bin/genefamilies/set/682>
- HGNC Gene Symbol Report
http://www.genenames.org/cgi-bin/gene_symbol_report?q=data/hgnc_data.php&hgnc_id=393

- NCBI Gene
<https://www.ncbi.nlm.nih.gov/gene/10000>
- UniProt
<http://www.uniprot.org/uniprot/Q9Y243>

Sources for This Summary

- Ballif BC, Rosenfeld JA, Traylor R, Theisen A, Bader PI, Ladda RL, Sell SL, Steinraths M, Surti U, McGuire M, Williams S, Farrell SA, Filiano J, Schnur RE, Coffey LB, Tervo RC, Stroud T, Marble M, Netzloff M, Hanson K, Aylsworth AS, Bamforth JS, Babu D, Niyazov DM, Ravnan JB, Schultz RA, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG. High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. *Hum Genet.* 2012 Jan;131(1):145-56. doi: 10.1007/s00439-011-1073-y.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/21800092>
- Cohen MM Jr. The AKT genes and their roles in various disorders. *Am J Med Genet A.* 2013 Dec; 161A(12):2931-7. doi: 10.1002/ajmg.a.36101. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/24039187>
- GeneReview: MPPH Syndrome
<https://www.ncbi.nlm.nih.gov/books/NBK396098>
- Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Matherne GW, Gleeson JG. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet.* 2012 Jun 24;44(8):941-5. doi: 10.1038/ng.2329.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22729223>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417942/>
- Mirzaa GM, Rivière JB, Dobyns WB. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP. *Am J Med Genet C Semin Med Genet.* 2013 May;163C(2): 122-30. doi: 10.1002/ajmg.c.31361. Epub 2013 Apr 16.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23592320>
- Nakamura K, Kato M, Tohyama J, Shiohama T, Hayasaka K, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Matsumoto N, Saitsu H. AKT3 and PIK3R2 mutations in two patients with megalencephaly-related syndromes: MCAP and MPPH. *Clin Genet.* 2014 Apr;85(4):396-8. doi: 10.1111/cge.12188.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23745724>
- Nellist M, Schot R, Hoogeveen-Westerveld M, Neuteboom RF, van der Louw EJ, Lequin MH, Bindels-de Heus K, Sibbles BJ, de Coo R, Brooks A, Mancini GM. Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia. *Mol Genet Metab.* 2015 Mar;114(3):467-73. doi: 10.1016/j.ymgme.2014.11.018.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/25523067>
- Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Rivello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA. Somatic activation of AKT3 causes hemispheric developmental brain malformations. *Neuron.* 2012 Apr 12; 74(1):41-8. doi: 10.1016/j.neuron.2012.03.010.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22500628>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460551/>

- Rivière JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzenruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL; Finding of Rare Disease Genes (FORGE) Canada Consortium, Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet*. 2012 Jun 24;44(8):934-40. doi: 10.1038/ng.2331.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22729224>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408813/>
- OMIM: V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3
<http://omim.org/entry/611223>
- Wang D, Zeesman S, Tarnopolsky MA, Nowaczyk MJ. Duplication of AKT3 as a cause of macrocephaly in duplication 1q43q44. *Am J Med Genet A*. 2013 Aug;161A(8):2016-9. doi: 10.1002/ajmg.a.35999.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23794269>

Reprinted from Genetics Home Reference:
<https://ghr.nlm.nih.gov/gene/AKT3>

Reviewed: January 2017
Published: March 21, 2017

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services